Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: A meta-analysis of randomized clinical trials

International Journal of Cardiology

Volumn 152, Issue 3, 2011, Pages 369-374

  Lee, Michael S ^a,b,c   Liao, Hsini ^b   Yang, Tae ^a,b,c   Dhoot, Jashdeep ^a,b,c   Tobis, Jonathan ^a,b,c   Fonarow, Gregg ^a,b,c   Mahmud, Ehtisham ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BOSTON SCIENTIFIC CORPORATION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bivalirudin; Glycoprotein IIb IIIa inhibitors; Heparin; Percutaneous coronary intervention

Indexed keywords

ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG;

ANTICOAGULATION; ARTICLE; BLEEDING; COMBINATION CHEMOTHERAPY; DEATH; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; INVASIVE PROCEDURE; META ANALYSIS; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; TREND STUDY;

ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HEPARIN; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS;

EID: 80055058132     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.08.007     Document Type: Article

References (24)

1. E.C. Keeley, J.A. Boura, and C.L. Grines Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials Lancet 361 2003 13 20
2. A.R. Gruentzig, A. Senning, and W.E. Siegenthaler Nonoperative dilation of coronary artery stenosis: percutaneous transluminal coronary angioplasty N Engl J Med 301 1979 61 71
3. The PURSUIT trial investigators Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes: platelet glycoprotein IIb/IIIa in unstable angina: Receptor Suppression Using Integrilin Therapy N Engl J Med 339 1998 436 443
4. J.L. Anderson, C.D. Adams, and E.M. Antman ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 50 2007 e1 e157
5. S.V. Rao, J.G. Jollis, and R.A. Harrington Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes JAMA 292 2004 1555 1562
6. J.W. Eikelboom, S.R. Mehta, and S.S. Anand Adverse impact of bleeding on prognosis in patients with acute coronary syndromes Circulation 114 2006 774 782
7. S.V. Manoukian, F. Feit, and R. Mehran Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial J Am Coll Cardiol 49 2007 1362 1368
8. I. Fox, A. Dawson, and P. Loynds Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans Thromb Haemost 69 1993 157 163
9. G.W. Stone, B. Witzenbichler, G. Guagliumi For the HORIZONS-AMI Trial Investigators Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230
10. A.M. Lincoff, J.A. Bittl, R.A. Harrington For the REPLACE-2 Investigators Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial JAMA 289 2003 853 863
11. G.W. Stone, B.T. McLaurin, D.A. Cox For the ACUITY Investigators Bivalirudin for patients with acute coronary syndromes N Engl J Med 355 2006 2203 2216
12. C.M. Gibson, D.A. Morrow, S.A. Murphy For the TIMI Study Group A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial J Am Coll Cardiol 47 2006 2364 2373
13. A.M. Lincoff, N.S. Kleiman, and K. Kottke-Marchant Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET) Am Heart J 143 2002 847 853
14. D.P. Chew, D.L. Bhatt, and W. Kimball Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials Am J Cardiol 92 2003 919 923
15. R. Ebrahimi, A.M. Lincoff, and J.A. Bittl Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis J Cardiovasc Pharmacol Ther 10 2005 209 216
16. E.M. Antman Should bivalirudin replace heparin during percutaneous coronary interventions (letter)? JAMA. 289 2003 903 905
17. J.A. Bittl Accounting for ACUITY (letter) N Engl J Med 355 2006 2249 2250
18. E.J. Topol, J.J. Ferguson, H.F. Weisman For the EPIC Investigator Group Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention JAMA 278 1997 479 484
19. A.M. Lincoff, J.E. Tcheng, and R.M. Califf Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one year outcome in the EPILOG trial Circulation 99 1999 1951 1958
20. R. Mehran, A.J. Lansky, and B. Witzenbichler Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomized controlled trial Lancet 374 2009 1149 1159
21. G.W. Stone, J.H. Ware, and M.E. Bertrand Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management JAMA 298 2007 2497 2506
22. R. Robson, H. White, and P. Aylward Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender Clin Pharmacol Ther 71 2002 433 439
23. D.P. Chew, D.L. Bhatt, and A.M. Lincoff Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials Circulation 103 2001 961 966
24. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150